 Cerebellar Neoplasms
"Cerebellar Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
| Descriptor ID |
D002528
|
| MeSH Number(s) |
C04.588.614.250.195.411.211 C10.228.140.211.500.200 C10.228.140.252.200 C10.551.240.250.400.300
|
| Concept/Terms |
Cerebellar Neoplasms- Cerebellar Neoplasms
- Cerebellar Tumors
- Cerebellar Tumor
- Tumor, Cerebellar
- Neoplasms, Cerebellar
- Cerebellar Neoplasm
- Neoplasm, Cerebellar
Cerebellar Neoplasms, Primary- Cerebellar Neoplasms, Primary
- Cerebellar Neoplasm, Primary
- Primary Cerebellar Neoplasm
- Primary Cerebellar Neoplasms
- Primary Neoplasms, Cerebellum
- Cerebellum Primary Neoplasm
- Cerebellum Primary Neoplasms
- Neoplasm, Cerebellum Primary
- Primary Neoplasm, Cerebellum
- Neoplasms, Cerebellar, Primary
Benign Cerebellar Neoplasms- Benign Cerebellar Neoplasms
- Benign Cerebellar Neoplasm
- Cerebellar Neoplasm, Benign
- Neoplasm, Benign Cerebellar
- Neoplasms, Cerebellar, Benign
- Cerebellar Neoplasms, Benign
Cerebellar Cancer- Cerebellar Cancer
- Cancer, Cerebellar
- Cerebellar Cancers
- Cerebellar Neoplasms, Malignant
- Neoplasms, Cerebellar, Malignant
- Malignant Cerebellar Neoplasms
- Cerebellar Neoplasm, Malignant
- Malignant Cerebellar Neoplasm
- Neoplasm, Malignant Cerebellar
|
Below are MeSH descriptors whose meaning is more general than "Cerebellar Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Cerebellar Neoplasms".
This graph shows the total number of publications written about "Cerebellar Neoplasms" by people in this website by year, and whether "Cerebellar Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 2007 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2012 | 9 | 0 | 9 | | 2013 | 1 | 0 | 1 | | 2014 | 4 | 0 | 4 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 1 | 4 | | 2020 | 5 | 0 | 5 | | 2021 | 7 | 0 | 7 | | 2022 | 7 | 0 | 7 | | 2023 | 5 | 0 | 5 | | 2024 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Cerebellar Neoplasms" by people in Profiles.
-
Abu-Arja MH, Brown AL, Su JM, Okcu MF, Lindsay HB, McGovern SL, McAleer MF, Grosshans DR, Chintagumpala MM, Paulino AC. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, Shahani P, Peterson K, Turos-Cabal M, Vieira ME, Wynn DT, Howell AJ, Yang F, Ban Y, McCrea HJ, Zindy F, Danis E, Vibhakar R, Jermakowicz A, Martin V, Coss CC, Harris BT, de Cubas A, Chen XS, Barnoud T, Roussel MF, Ayad NG, Robbins DJ. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. J Clin Invest. 2024 Jun 17; 134(15).
-
Lindsay HB, Scheurer ME, Allam AK, Lucas BJ, McGovern SL, Chintagumpala M, Paulino AC. Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
-
Nellan A, Jackson S. Targeted therapy done right: Direct sonic hedgehog inhibition for sonic hedgehog medulloblastoma. Neuro Oncol. 2024 04 05; 26(4):623-624.
-
Smalling S, Roberts J, Hendrick K, Gray M, Wyrwa JM. Vestibular Testing and Impairments in Postoperative Pediatric Cerebellar Mutism Syndrome: A Case Series. Pediatr Neurol. 2024 May; 154:15-19.
-
Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, Hsu JY, Oliphant MUJ, Armstrong B, Wessells V, Varella-Garcia M, Galbraith MD, Pierce A, Wang D, Venkataraman S, Danis E, Veo B, Serkova N, Espinosa JM, Gustafson DL, Vibhakar R, Ford HL. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro Oncol. 2023 12 08; 25(12):2287-2301.
-
Okonechnikov K, Joshi P, Sepp M, Leiss K, Sarropoulos I, Murat F, Sill M, Beck P, Chan KC, Korshunov A, Sah F, Deng MY, Sturm D, DeSisto J, Donson AM, Foreman NK, Green AL, Robinson G, Orr BA, Gao Q, Darrow E, Hadley JL, Northcott PA, Gojo J, Kawauchi D, Hovestadt V, Filbin MG, von Deimling A, Zuckermann M, Pajtler KW, Kool M, Jones DTW, J?ger N, Kutscher LM, Kaessmann H, Pfister SM. Mapping pediatric brain tumors to their origins in the developing cerebellum. Neuro Oncol. 2023 10 03; 25(10):1895-1909.
-
McSwain LF, Pillsbury CE, Haji-Seyed-Javadi R, Rath SK, Chen V, Huang T, Shahab SW, Kunhiraman H, Ross J, Price GA, Dey A, Hambardzumyan D, MacDonald T, Yu DS, Porter CC, Kenney AM. YB1 modulates the DNA damage response in medulloblastoma. Sci Rep. 2023 05 19; 13(1):8087.
-
Shishido K, Purvis IJ, Velpula KK, Venkataraman S, Vibhakar R, Asuthkar S. Targeting B7-H3 through EZH2 inhibition in MYC-positive Group 3 medulloblastoma. Oncol Rep. 2023 Jun; 49(6).
-
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Bl?mel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, W?lfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, St?hler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. J Immunother Cancer. 2023 01; 11(1).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|